|
|
Vaccine Detail
|
VHL-42: 65-76(V74G) Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: VHL-42: 65-76(V74G) Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007175
- Type: Peptide Vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- VHL
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: All peptides were custom-designed based on the patient's own tumor VHL mutation and the potential binding affinity of the amino acid motif spanning the mutation to the patient's HLA. The vaccine consisted of a dose of 1000 μg of the emulsified corresponding mutant VHL peptide and Montanide ISA-51 (Rahma et al., 2010).
- Description: This is for Renal Cancer. A peptide vaccine consisting of amino acids 65 through 76 derived from the tumor suppressor protein Von Hippel-Lindau (VHL) with a glycine substitution at position 74. As a cancer vaccine, VHL-59: 65-76(V74G) may stimulate a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing this VHL mutant protein (Rahma et al., 2010; NCIT_C38122).
|
| Host Response |
|
|
| References |
NCIT_C38122: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38122]
Rahma et al., 2010: Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. Journal of translational medicine. 2010; 8; 8. [PubMed: 20109232].
|
|
